Arzu Yorgancıoğlu
A5056266797- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Respiratory and Cough-Related Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Inhalation and Respiratory Drug Delivery
- Delphi Technique in Research
- Health and Medical Studies
- School Health and Nursing Education
- Pediatric health and respiratory diseases
- Respiratory Support and Mechanisms
- Air Quality and Health Impacts
- Pharmaceutical studies and practices
- Climate Change and Health Impacts
- Health and Wellbeing Research
- Health Systems, Economic Evaluations, Quality of Life
- Behavioral Health and Interventions
- Lung Cancer Diagnosis and Treatment
- Food Allergy and Anaphylaxis Research
- COVID-19 Clinical Research Studies
- Nasal Surgery and Airway Studies
- Dermatology and Skin Diseases
- Global Health Care Issues
- Eosinophilic Esophagitis
- Olfactory and Sensory Function Studies
- Tracheal and airway disorders
Manisa Celal Bayar University
2016-2025
ENT and Allergy
2021-2024
Sağlık Bilimleri Üniversitesi
2023
University of Bath
2023
Dokuz Eylül University
2023
University of Minnesota
2023
American Thoracic Society
2023
University of North Carolina at Chapel Hill
2023
Woolcock Institute of Medical Research
2023
Observational & Pragmatic Research Institute
2023
Indacaterol is the first once-daily, long-acting inhaled beta(2)-agonist bronchodilator studied in patients with chronic obstructive pulmonary disease (COPD).To demonstrate greater efficacy of indacaterol versus placebo on FEV(1) at 24 hours post dose (trough) after 12 weeks, to compare and tiotropium, evaluate safety tolerability over 26 weeks.Patients moderate-to-severe COPD were randomized double-blind 150 or 300 microg placebo, open-label tiotropium 18 microg, all once daily, for weeks....
<b>GINA no longer recommends treating adults/adolescents with asthma short-acting bronchodilators alone. Instead, they should receive symptom-driven (in mild asthma) or a daily corticosteroid-containing inhaler, to reduce risk of severe exacerbations.</b>http://bit.ly/310LLzE
The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy asthma management and prevention, which can be adapted local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, the evidence underpinning recent changes. recommends that in adults adolescents should not treated solely short-acting β2-agonist (SABA), because of risks SABA-only treatment SABA overuse, benefit...
The coronavirus disease 2019 (COVID-19) has evolved into a pandemic infectious transmitted by the severe acute respiratory syndrome (SARS-CoV-2). Allergists and other healthcare providers (HCPs) in field of allergies associated airway diseases are on front line, taking care patients potentially infected with SARS-CoV-2. Hence, strategies practices to minimize risks infection for both HCPs treated have be developed followed allergy clinics.The scientific information COVID-19 was analysed...
Mobile technology has been used to appraise allergic rhinitis control, but more data are needed. To better assess the importance of mobile technologies in ARIA (Allergic Rhinitis and its Impact on Asthma) score ranging from 0 4 Allergy Diary was compared with EQ-5D (EuroQuol) WPAI-AS (Work Productivity Activity Impairment allergy) 1288 users 18 countries. This study showed that quality-of-life (EQ-5D visual analogue scale WPA-IS Question 9) similar without those mild (scores 0-2). Users a 3...
Although there are many asymptomatic patients, one of the problems COVID-19 is early recognition disease. symptoms polymorphic and may include upper respiratory symptoms. However, be mistaken with common cold or allergic rhinitis. An ARIA-EAACI study group attempted to differentiate between three diseases.A modified Delphi process was used. The ARIA members who were seeing patients asked fill in a questionnaire on airway COVID-19, rhinitis.Among 192 invited respond questionnaire, 89...
Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed use real-life data from MASK-air® app generate and validate hypothesis- data-driven CSMSs.We used assess concurrent validity, test-retest reliability responsiveness one hypothesis-driven CSMS (modified CSMS: mCSMS), mixed score (mixed score), several CSMSs. The latter were generated with following cluster analysis regression models or factor analysis....